News

The agreement is a second transaction between Altacor and Ophthalmopharma in which Altacor assumes responsibilities for their entire portfolio of ophthalmic products covering development, IP and commercialisation of

Wedgewood Pharmacy makes customized prescription medications when FDA approved manufactured drugs like Cytarabine which are not available or when human and animal patients need a special dosage-form or

ARGENT gene expression regulation technology is expected to add a valuable tool to Regenx’s NAV platform by providing control of gene expression and the potential for safety and

Through the collaboration with University of Minnesota and James Cloyd, Neurelis has also partnered with experts in clinical research of the nasal delivery of benzodiazepines. The company expects

ANAVEX 2-73 is the first of a new class of oral, disease-modifying drugs being studied to potentially treat AD itself, versus treating its symptoms. The Phase I clinical

The execution of the trial entitles Dynavax to receive a $6m milestone payment from GSK, its partner in a worldwide strategic alliance. As per the terms of the

The study results showed increase in lumbar spine bone mineral density at month 12 for the AMG 785/CDP7851 active arms versus the placebo arm. The study was planned

Elan’s net income was $68.2m, or $0.12 per diluted share, compared to a net loss of $6.8m, or $0.01 per diluted share, for the same period in 2010.

The new EMR suite will ease challenges and will offer safe, secure and user- friendly access for patients, according to the company. Keeping patient’s records in a single